Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Vivancos, P
Nov 17: AstraZeneca scored a first-in-class approval for its pan-AKT inhibitor capivasertib as a treatment for adults with hormone receptorpositive and HER2-negative locally advanced or metastatic breast cancer whose tumors also have PIK3CA, AKT1 or PTEN mutations
Hyperammonemia compromises glutamate metabolism and reduces BDNF in the rat hippocampus
This limitation may also explain the lack of significant, measurable changes in key metabolites such as TRP, KYNA, and LKYN, which are critical components of the kynurenine pathway
US$ 20.60
US$ 21.71
US$ 21.71
US$ 23.42
US$ 24.70
US$ 22.75
